Search

Your search keyword '"ROS1 Rearrangement"' showing total 154 results

Search Constraints

Start Over You searched for: Descriptor "ROS1 Rearrangement" Remove constraint Descriptor: "ROS1 Rearrangement"
154 results on '"ROS1 Rearrangement"'

Search Results

1. Exceptional long term response to crizotinib in ROS 1‐postive advanced non small cell lung cancer.

2. Exceptional long term response to crizotinib in ROS 1‐postive advanced non small cell lung cancer

Catalog

Books, media, physical & digital resources

3. A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens

4. Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer

5. Progress of non-small-cell lung cancer with ROS1 rearrangement

6. A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens.

7. Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report

8. A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer.

9. The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China

10. ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.

11. Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report

12. The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China.

13. Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer.

14. A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib

15. First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

16. ROS1

17. Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report.

18. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.

19. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

20. Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report

21. Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report.

22. Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report

23. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

24. A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.

25. First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer.

27. Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report

28. Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer

29. Progress of non-small-cell lung cancer with ROS1 rearrangement.

30. A genomic and clinicopathological study of non‐small‐cell lung cancers with discordant ROS1 gene status by fluorescence in‐situ hybridisation and immunohistochemical analysis.

31. Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement

32. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer

33. Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.

34. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.

35. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

36. The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non–Small-Cell Lung Cancer

37. First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

38. A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib

39. Emerging targeted therapies in non-small cell lung cancer.

40. ROS1 pattern of immunostaining in 11 cases of spitzoid tumour: comparison with histopathological, fluorescence in-situ hybridisation and next-generation sequencing analysis

41. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?

42. Deepening the knowledge of ros1 rearrangements in non-small cell lung cancer: Diagnosis, treatment, resistance and concomitant alterations

43. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

44. TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

45. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.

46. ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report

47. Second-Line Therapy for Advanced NSCLC.

49. FP12.08 Lung Adenocarcinomas with ROS1 Rearrangement show Diffuse Strong ROS1 Immunohistochemical Staining